非布索坦治疗痛风患者疗效怎样呢？

How effective is (Febuxostat) in treating gout patients?

According to the research results, long-term use of Febuxostat (Febuxostat) can maintain long-term blood uric acid in most patients at ≤6.0 mg/dl. Mild to moderate impairment of renal function has no significant impact on the pharmacodynamics and pharmacokinetics of Febuxostat (Febuxostat). Therefore, the uric acid-lowering effect of Febuxostat (Febuxostat) is no different from that of patients with normal renal function, and its safety is good. Moreover, febuxostat (febuxostat) has a better uric acid-lowering effect than allopurinol without serious adverse reactions, and has good clinical application prospects.

Febuxostat (Febuxostat) is completely absorbed after oral administration, with a bioavailability of approximately 85%, a peak time of approximately 1 hour, and a half-life of 5 to 8 hours. Food and antacids have no significant effect on the absorption of febuxostat. Febuxostat can be used in combination with other drugs, such as colchicine (0.6 mg twice a day), certain non-steroidal anti-inflammatory drugs hydrochlorothiazide, warfarin, desimipramine, etc., without significant impact on the pharmacokinetics of the two, and no dose adjustment is required. However, it is currently not recommended to use febuxostat in combination with azathioprine and mercaptopurine because the latter two are metabolized by xanthine oxidase.

The currently recommended application method is: the initial dose is 40 mg/d. If the blood uric acid has not reached ≤6.0 mg/dl after 2 weeks, increase the dose to 80 mg/d. The drug is mainly metabolized by the liver and does not rely on renal excretion. Therefore, it is safe and effective for patients with mild to moderate renal insufficiency, and no dose adjustment is required.

Clinically, the use of febuxostat (febuxostat) should be considered for patients with mild to moderate renal impairment, allopurinol intolerance, and current treatments that cannot maintain blood uric acid at the target value. In addition, when febuxostat is used to treat hyperuricemia, it may easily lead to an acute attack of gout in the early stages. Therefore, it is recommended that patients taking (febuxostat) combined with colchicine or non-steroidal anti-inflammatory drugs for the first 6 months of treatment to avoid acute attacks of gout.

Recommended related articles: